Cipla said the USFDA has classified its April inspection of the company’s Goa manufacturing facility as Voluntary Action Indicated (VAI), a status under which observations are expected to be addressed voluntarily without regulatory action.
Cipla said the USFDA has classified its April inspection of the company’s Goa manufacturing facility as Voluntary Action Indicated (VAI), a status under which observations are expected to be addressed voluntarily without regulatory action.